Energy and Commerce’s health care plans
This article was originally published in The Tan Sheet
The House Energy and Commerce Committee's oversight plan for the 111th Congress includes assessing "whether necessary safeguards for imported drugs are in place," which is a focus of the FDA Globalization Act co-sponsored by former committee chairman John Dingell, D-Mich. (1"The Tan Sheet" Feb. 2, 2009, p. 6). Energy and Commerce also will examine manufacturing practices for Rx and nonprescription drugs and investigate off-label marketing of Rx drugs. House committees must submit oversight plans to the Oversight and Government Reform Committee and the House Administration Committee near the start of each session. The plans outline topics committees want to address, but the panels can narrow or expand their work during a session
You may also be interested in...
At an upcoming hearing, House Energy and Commerce Committee leaders will question executives from labs that tested ingredients at the peanut processing facility linked to widespread recalls due to salmonella contamination
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.